Brian Yang

Beijing

Managing Editor at The Pink Sheet

Managing Editor at Scrip

Health business writer covering China, mRNA vaccines, new drugs, biotech from Beijing

Featured in: Favicon

informa.com (+6) Favicon

patch.com

energypost.eu Favicon

pharmamedtechbi.com Favicon

mttlr.org

allageless.com Favicon

lexology.com Favicon

statnews.com Favicon

citeline.com (+1) Favicon

wiley.com + 1 more

Articles

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

2 weeks ago | insights.citeline.com | Brian Yang

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck DealCrystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

3 weeks ago | insights.citeline.com | Brian Yang

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership01 Apr 2025 • By Brian YangDespite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
Asia On The Move: Personnel News From AstraZeneca, Novartis, Teva

4 weeks ago | insights.citeline.com | Brian Yang

Asia On The Move: Personnel News From AstraZeneca, Novartis, TevaAstraZeneca Japan appoints a 38-year old president, Novartis Japan selects a woman CEO and Teva recruits a Lilly veteran to head its operation in Japan. These moves and others are profiled in this edition of Asia On The Move.
These 12 Chinese companies are poised to transform CRISPR gene-editing

1 month ago | statnews.com | Brian Yang

As the race between U.S. and Chinese biotech companies heats up, the competition is particularly fierce in one field: CRISPR gene editing. China has rapidly emerged as a global leader in CRISPR research. While much of the initial focus in the industry was on the use of the technology to develop cancer treatments, Chinese biotech firms have since moved to apply it to test therapies for rare diseases, including sickle cell disease and inherited eye disorders.
Thinking about colonial institutions through a framework of hoarding

1 month ago | anthrosource.onlinelibrary.wiley.com | Brian Yang

The topic of “colonial hoarding” was the focus of a roundtable at the 2023 joint meeting of the American Anthropological Association and Canadian Anthropology Society, and it is also the focus of this commentary cluster.1 In the roundtable session, I invited participants to examine how colonial institutions that maintain ethnographic collections, such as museums, universities, and private collections, conform to (and diverge from) the diagnostic criteria for hoarding disorder described by the...
DeepSeek signals China’s rising influence in AI — and AI drug development

2 months ago | statnews.com | Brian Yang

Is China setting the global standard for AI-driven drug development? DeepSeek, a relatively unknown AI firm based in Hangzhou, China, shocked the industry last week with claims that its technology could rival the abilities of technologies developed by leading U.S. AI companies — and do so far more economically.
China FDA Highlights Product Recalls, Manufacturers Urged To Make Rapid Responses

Dec 18, 2024 | insights.citeline.com | Brian Yang

China FDA Highlights Product Recalls, Manufacturers Urged To Make Rapid ResponsesDespite being one of the largest medical product markets in the world, China has seen few product recalls. The situation could be changing however as China FDA has requested drug and device manufacturers to quickly withdraw products that have deficiencies and potential safety risks.
Probe of AstraZeneca executive in China raises questions about company’s tactics

Nov 4, 2024 | statnews.com | Brian Yang

ANDREW YATES/AFP via Getty Images By Brian Yang The U.K. pharmaceutical company AstraZeneca has become the largest multinational drugmaker in China, drawing 13% of its $5.8 billion in revenue last year from there, against a backdrop of an acute economic slowdown in the country and a major anti-corruption campaign aimed at the health care industry. Now, the question is whether AstraZeneca became overly aggressive in its ambitions. Last week, the company disclosed that Leon Wang, its executive...
VCs move to launch U.S.-based companies to advance drugs developed in China

Oct 29, 2024 | statnews.com | Brian Yang

Adobe By Brian Yang As Chinese biopharma companies rise on the international stage, they are increasingly finding VC partners — in the United States.
RemeGen Rises, Falls Along With Chinese Antibody Ambitions

Oct 28, 2024 | insights.citeline.com | Brian Yang

RemeGen Rises, Falls Along With Chinese Antibody AmbitionsDiscipline, Deals Key? Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors. RemeGen's stock price hit in apparent reflection of multiple challenges • Source: Shutterstock